Literature DB >> 8167208

Dopamine D2 receptors in depression measured with single photon emission computed tomography.

H A D'haenen1, A Bossuyt.   

Abstract

Psychobiological theories of mood disorders have been concerned mainly with noradrenaline and serotonin. There exists, however, a recent upsurge of interest in dopamine. We have used single photon emission computed tomography and 123I-iodobenzamide, a high-affinity ligand for D2 receptors, to study these receptors in depression. Subjects were 21 (unipolar) depressed inpatients and 11 normal controls. The mean basal ganglia/cerebellum uptake ratio was 1.94 (+/- 0.27) in the depressed patients versus 1.74 (+/- 0.17) in the controls. This difference was statistically significant (Mann-Whitney U test, p = 0.025). These data could indicate an increase of D2 receptor density in depression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167208     DOI: 10.1016/0006-3223(94)91202-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  41 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

3.  Elevated dopamine D1 receptor availability in striatum of Göttingen minipigs after electroconvulsive therapy.

Authors:  Anne M Landau; Aage Ko Alstrup; Helene Audrain; Steen Jakobsen; Mette Simonsen; Arne Møller; Poul Videbech; Gregers Wegener; Albert Gjedde; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-16       Impact factor: 6.200

Review 4.  Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Authors:  Jennifer C Felger; Michael T Treadway
Journal:  Neuropsychopharmacology       Date:  2016-08-02       Impact factor: 7.853

5.  Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings.

Authors:  Julia P Dunn; Ronald L Cowan; Nora D Volkow; Irene D Feurer; Rui Li; D Brandon Williams; Robert M Kessler; Naji N Abumrad
Journal:  Brain Res       Date:  2010-03-31       Impact factor: 3.252

6.  Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis.

Authors:  Michael T Treadway; Diego A Pizzagalli
Journal:  Biol Mood Anxiety Disord       Date:  2014-03-07

7.  Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.

Authors:  Marta Peciña; Magdalena Sikora; Erich T Avery; Joseph Heffernan; Susana Peciña; Brian J Mickey; Jon-Kar Zubieta
Journal:  Eur Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 4.600

8.  Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli.

Authors:  Andrea Kobiella; Sabine Vollstädt-Klein; Mira Bühler; Caroline Graf; Hans-Georg Buchholz; Nina Bernow; Igor Y Yakushev; Christian Landvogt; Mathias Schreckenberger; Gerhard Gründer; Peter Bartenstein; Christoph Fehr; Michael N Smolka
Journal:  Hum Brain Mapp       Date:  2010-05       Impact factor: 5.038

9.  Dopamine and depression--striatal dopamine D2 receptor SPECT before and after antidepressant therapy.

Authors:  D Ebert; H Feistel; T Loew; A Pirner
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

10.  DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder.

Authors:  Jonathan Savitz; Colin A Hodgkinson; Chantal Martin-Soelch; Pei-Hong Shen; Joanna Szczepanik; Allison C Nugent; Peter Herscovitch; Anthony A Grace; David Goldman; Wayne C Drevets
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-20       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.